Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stock Report

Market Cap: SEK 97.9b

Swedish Orphan Biovitrum Management

Management criteria checks 3/4

Swedish Orphan Biovitrum's CEO is Guido Oelkers, appointed in May 2017, has a tenure of 8.08 years. total yearly compensation is SEK55.53M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth SEK151.13M. The average tenure of the management team and the board of directors is 5.4 years and 3.3 years respectively.

Key information

Guido Oelkers

Chief executive officer

SEK 55.5m

Total compensation

CEO salary percentage24.51%
CEO tenure8.1yrs
CEO ownership0.2%
Management average tenure5.4yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

May 02
Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings

Apr 18
Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings

Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?

Feb 28
Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?

Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 07
Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet

Jan 21
Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet

Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Dec 30
Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
author-image

Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio

Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

CEO Compensation Analysis

How has Guido Oelkers's remuneration changed compared to Swedish Orphan Biovitrum's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

SEK 4b

Dec 31 2024SEK 56mSEK 14m

SEK 4b

Sep 30 2024n/an/a

SEK 4b

Jun 30 2024n/an/a

SEK 2b

Mar 31 2024n/an/a

SEK 2b

Dec 31 2023SEK 49mSEK 12m

SEK 2b

Sep 30 2023n/an/a

SEK 3b

Jun 30 2023n/an/a

SEK 3b

Mar 31 2023n/an/a

SEK 3b

Dec 31 2022SEK 47mSEK 11m

SEK 3b

Sep 30 2022n/an/a

SEK 2b

Jun 30 2022n/an/a

SEK 3b

Mar 31 2022n/an/a

SEK 3b

Dec 31 2021SEK 42mSEK 10m

SEK 3b

Sep 30 2021n/an/a

SEK 3b

Jun 30 2021n/an/a

SEK 3b

Mar 31 2021n/an/a

SEK 3b

Dec 31 2020SEK 33mSEK 10m

SEK 3b

Sep 30 2020n/an/a

SEK 3b

Jun 30 2020n/an/a

SEK 3b

Mar 31 2020n/an/a

SEK 4b

Dec 31 2019SEK 33mSEK 10m

SEK 3b

Sep 30 2019n/an/a

SEK 3b

Jun 30 2019n/an/a

SEK 3b

Mar 31 2019n/an/a

SEK 3b

Dec 31 2018SEK 26mSEK 9m

SEK 2b

Compensation vs Market: Guido's total compensation ($USD5.85M) is above average for companies of similar size in the Swedish market ($USD3.05M).

Compensation vs Earnings: Guido's compensation has been consistent with company performance over the past year.

CEO

Guido Oelkers (60 yo)

8.1yrs
Tenure
SEK 55,533,000
Compensation

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Leadership Team

NamePositionTenureCompensationOwnership
Guido Oelkers
CEO & President8.1yrsSEK 55.53m0.15%
SEK 151.1m
Henrik Stenqvist
Chief Financial Officer6.9yrsno data0.023%
SEK 22.5m
Torbjörn Hallberg
General Counsel & Head of Legal Affairs6.4yrsno data0.015%
SEK 14.4m
Daniel Rankin
Head of Strategy & Corporate Development3.4yrsno data0.0025%
SEK 2.4m
Lena Bjurner
Head of Human Resources2.4yrsno datano data
Norbert Oppitz
Head of International7.7yrsno data0.018%
SEK 17.7m
Sofiane Fahmy
Head of Europe6.4yrsno data0.014%
SEK 13.4m
Duane Barnes
Head of North America4.4yrsno data0.0050%
SEK 4.9m
Mahmood Ladha
Head of Strategic Transformation Operationsno datano data0.0055%
SEK 5.3m
Christine Wesstrom
Head of Technical Operations3.3yrsno data0.0054%
SEK 5.3m
Lydia Abad-Franch
Senior VP2.4yrsno data0.0018%
SEK 1.7m
5.4yrs
Average Tenure
57yo
Average Age

Experienced Management: SOBI's management team is seasoned and experienced (5.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hans Wigzell
Chairman of Scientific Advisory Board24.4yrsSEK 158.00kno data
Helena Saxon
Director14.2yrsSEK 101.00k0.0066%
SEK 6.5m
Anders Ullman
Director2.1yrsSEK 648.00k0.0010%
SEK 978.9k
Stephen O'Rahilly
Member of Scientific Advisory Boardno datano datano data
Ralf Pettersson
Member of Scientific Advisory Boardno datano datano data
Stefan Del Prato
Member of Scientific Advisory Boardno datano datano data
Jonathan Sanders Arch
Member of Scientific Advisory Boardno datano datano data
Staffan Schuberg
Independent Director5.1yrsSEK 907.00k0.0021%
SEK 2.0m
Filippa Stenberg
Director4.1yrsSEK 733.00k0.00017%
SEK 166.4k
David Meek
Independent Chairmanless than a yearSEK 175.00kno data
Katy Mazibuko
Employee Representative Director2.4yrsno data0.0013%
SEK 1.2m
Christophe Bourdon
Independent Director2.1yrsSEK 700.00kno data
3.3yrs
Average Tenure
55.5yo
Average Age

Experienced Board: SOBI's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/13 13:47
End of Day Share Price 2025/06/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Xue ChenBarclays
Rosie TurnerBarclays